Indivior stock price target raised to $34 from $27 at Craig-Hallum

Indivior (NASDAQ:INDV) reported robust Q2 2025 results, significantly surpassing EPS and revenue forecasts, while detailing its multi-year 'Action Agenda' to restructure operations, focus on the U.S. market, and drive revenue growth into 2026, including substantial headcount reductions. This strategic clarity and strong financial performance prompted Craig-Hallum to raise its price target to $34.00 and maintain a Buy rating, reinforcing the stock's 175% return over the past six months. Despite anticipated restructuring charges of $39M-$50M, Piper Sandler also reiterated its Overweight rating, signaling continued analyst confidence in the pharmaceutical company's operational efficiency and future outlook.

Analysis

Indivior is demonstrating significant operational momentum and strategic clarity, underpinned by a robust Q2 2025 financial performance. The company reported earnings per share of $0.51, more than double the forecast of $0.24, and revenue of $302 million, which surpassed projections by nearly 25%. This strong execution coincides with the launch of its "Action Agenda," a multi-year restructuring plan designed to sharpen its focus on the U.S. market, particularly its Sublocade product and the broader long-acting injectable (LAI) segment. Analyst confidence is high, with Craig-Hallum raising its price target to $34.00 from $27.00, citing the material impact of the restructuring, and Piper Sandler reiterating its Overweight rating. While the stock's 175% return over the past six months reflects strong positive sentiment, investors should note the planned restructuring will incur charges between $39 million and $50 million, with the full financial implications and details on headcount reductions not due until late October. The new strategic direction provides a clear roadmap for revenue growth into 2026, but its execution and associated costs remain a key variable to monitor.

Key Decisions for Investors

• The strong earnings beat and clear strategic pivot towards the U.S. LAI market, validated by multiple positive analyst ratings, support a bullish thesis for the stock's continued outperformance.
• Investors must closely monitor the late October update for full financial details on the restructuring, as the $39M-$50M in charges and headcount reductions represent a key risk and source of potential near-term volatility.
• Considering the stock's 175% appreciation in the last six months, it may be prudent to evaluate valuation and entry points, as much of the recent positive news may already be reflected in the current share price trading near its 52-week high.